Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HECTOR GRANADOS

Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology

NPI
1154616068
CMS profile
1273962
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$18,087.86

70 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HECTOR GRANADOS

NPI 1154616068 · CMS profile ID 1273962

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Endocrinology

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154616068?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HECTOR GRANADOS, NPI 1154616068, CMS profile ID 1273962. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154616068?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HECTOR GRANADOS, NPI 1154616068, CMS profile ID 1273962. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154616068?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HECTOR GRANADOS, NPI 1154616068, CMS profile ID 1273962, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–70 of 70 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1154616068?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

70 matching records · $18,087.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 70 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–70 of 70.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insulet Corporation $1,200.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842613 CMS
Insulet Corporation $1,200.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842611 CMS
Insulet Corporation $8.7804/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839825989 CMS
SANOFI-AVENTIS U.S. LLC $18.3604/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843395235 CMS
Xeris Pharmaceuticals, Inc. $16.6604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837423900 CMS
Insulet Corporation $400.0004/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842637 CMS
Insulet Corporation $400.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842635 CMS
AbbVie Inc. $24.5103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794655212 CMS
Abbott Laboratories $16.8003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818443119 CMS
Insulet Corporation $800.0003/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842623 CMS
TOLMAR Pharmaceuticals, Inc. $16.1103/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836507331 CMS
DEXCOM, INC. $0.6503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845279113 CMS
Insulet Corporation $800.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842621 CMS
Abbott Laboratories $16.1503/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818428121 CMS
Insulet Corporation $90.0802/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839821939 CMS
AbbVie Inc. $17.3202/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794655209 CMS
Medtronic, Inc. $11.6502/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815650897 CMS
Insulet Corporation $400.0001/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842633 CMS
AbbVie Inc. $23.5201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794655204 CMS
Insulet Corporation $1,200.0001/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839842609 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,127.22 19
PY2020 $18,402.34 53
PY2021 $18,087.86 70
PY2022 $31,203.68 96
PY2023 $1,206.65 53
PY2024 $1,183.41 41
PY2025 $1,124.30 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $26,653.45 6
PY2025 Principal investigator $54,462.93 35
PY2024 Recipient $17,000.00 2
PY2024 Principal investigator $42,388.75 39
PY2023 Principal investigator $52,953.65 9
PY2022 Principal investigator $15,897.87 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Antares Pharma, Inc. $900.00 12/23/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235889025
Principal investigator 1 Antares Pharma, Inc. $35.00 11/04/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888981
Principal investigator 1 Antares Pharma, Inc. $334.33 10/13/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888957
Principal investigator 1 Antares Pharma, Inc. $2,420.50 09/22/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888954
Principal investigator 1 Antares Pharma, Inc. $15.00 09/09/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888942
Principal investigator 1 Antares Pharma, Inc. $250.00 09/08/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888937
Recipient Ascendis Pharma Endocrinology Inc $6,158.25 09/04/2025 Covered Recipient Physician SkybriGHt No dispute reported 06/30/2026 1233996749
Recipient Ascendis Pharma Endocrinology Inc $5,888.80 09/04/2025 Covered Recipient Physician SkyPASS No dispute reported 06/30/2026 1233996751
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,567.40 09/04/2025 Non-covered Recipient Entity
Medresearch Inc
SkybriGHt No dispute reported 06/30/2026 1233996753
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,472.20 09/04/2025 Non-covered Recipient Entity
Medresearch Inc
SkyPASS No dispute reported 06/30/2026 1233996755
Principal investigator 1 Antares Pharma, Inc. $7,839.71 09/01/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888934
Recipient Ascendis Pharma Endocrinology Inc $5,632.95 08/26/2025 Covered Recipient Physician SkybriGHt No dispute reported 06/30/2026 1233996695
Recipient Ascendis Pharma Endocrinology Inc $5,080.45 08/26/2025 Covered Recipient Physician SkyPASS No dispute reported 06/30/2026 1233996697
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,742.95 08/26/2025 Non-covered Recipient Entity
Medresearch Inc
SkybriGHt No dispute reported 06/30/2026 1233996705
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,576.35 08/26/2025 Non-covered Recipient Entity
Medresearch Inc
SkyPASS No dispute reported 06/30/2026 1233996707
Recipient Ascendis Pharma Endocrinology Inc $2,052.75 07/31/2025 Covered Recipient Physician SkybriGHt No dispute reported 06/30/2026 1233996589
Recipient Ascendis Pharma Endocrinology Inc $1,840.25 07/31/2025 Covered Recipient Physician SkyPASS No dispute reported 06/30/2026 1233996597
Principal investigator 1 Antares Pharma, Inc. $25.00 07/28/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888910
Principal investigator 1 Antares Pharma, Inc. $10.00 07/11/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888901
Principal investigator 1 Antares Pharma, Inc. $3,991.84 07/11/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888906
Principal investigator 1 Ascendis Pharma Endocrinology Inc $850.00 06/25/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233996031
Principal investigator 1 Antares Pharma, Inc. $40.00 06/20/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888893
Principal investigator 1 Antares Pharma, Inc. $15.00 06/20/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888897
Principal investigator 1 Antares Pharma, Inc. $900.00 06/04/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888889
Principal investigator 1 Antares Pharma, Inc. $26.50 06/03/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888885
Principal investigator 1 Ascendis Pharma Endocrinology Inc $75.00 04/12/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233995521
Principal investigator 1 SANOFI US SERVICES INC. $1,492.00 04/11/2025 Non-covered Recipient Entity
Hector Granados, Md, Pa
A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) No dispute reported 06/30/2026 1226089509
Principal investigator 1 SANOFI US SERVICES INC. $1,492.00 04/11/2025 Non-covered Recipient Entity
Hector Granados, Md, Pa
A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) No dispute reported 06/30/2026 1226089515
Principal investigator 1 SANOFI US SERVICES INC. $1,492.00 04/11/2025 Non-covered Recipient Entity
Hector Granados, Md, Pa
A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) No dispute reported 06/30/2026 1226089521
Principal investigator 1 SANOFI US SERVICES INC. $8,500.00 04/11/2025 Non-covered Recipient Entity
Hector Granados, Md, Pa
A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) No dispute reported 06/30/2026 1226089528
Principal investigator 1 SANOFI US SERVICES INC. $250.00 04/11/2025 Non-covered Recipient Entity
Hector Granados, Md, Pa
A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL) No dispute reported 06/30/2026 1226089534
Principal investigator 1 Antares Pharma, Inc. $40.00 03/25/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888849
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,211.40 03/05/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233994989
Principal investigator 1 Antares Pharma, Inc. $8,000.00 02/04/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888838
Principal investigator 1 Antares Pharma, Inc. $1,150.00 02/04/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888842
Principal investigator 1 Antares Pharma, Inc. $1,010.00 02/04/2025 Non-covered Recipient Entity
MEDRESEARCH INC
Open-Label Multiple-Dose 52-Week Study to Evaluate the Safety PK & Efficacy of XYOSTED for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism No dispute reported 06/30/2026 1235888846
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,587.60 01/18/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233993986
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,211.40 01/18/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233993994
Principal investigator 1 Ascendis Pharma Endocrinology Inc $850.00 01/18/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233993996
Principal investigator 1 Ascendis Pharma Endocrinology Inc $75.00 01/18/2025 Non-covered Recipient Entity
Medresearch Inc
New InsiGHts No dispute reported 06/30/2026 1233994020
Principal investigator 1 Rhythm Pharmaceuticals, Inc. $14.75 01/02/2025 Non-covered Recipient Entity
Harmony United Research LLC
DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway No dispute reported 06/30/2026 1240080744